[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614682":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":31,"responsibleParty":37,"collaborators":31,"id":39,"slug":31,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":31,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":31,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":64,"whyStopped":31,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":31},{"fullName":5,"class":6},"University of Chicago","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide (Wegovy)","EXPERIMENTAL","Participants will receive semaglutide (Wegovy) weekly for 8 weeks.",[13],"Drug: Semaglutide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Semaglutide","All participants in the study will receive semaglutide (Wegovy).",[9],[21],"Wegovy",[23],{"name":24,"affiliation":5,"role":25},"Jon E Grant, MD, JD, MPH","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Sofia Vicenzino, BA","CONTACT","773-702-9066",null,"sofia.vicenzino@bsd.uchicago.edu",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Estelle Spira, BS","773-834-3778","estelle.spira@bsd.uchicago.edu",{"type":38,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100614682",false,"NCT07282769","Semaglutide (Wegovy) Treatment for Trichotillomania","Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study","Inclusion Criteria:\n\n1. Men and women age 18-75;\n2. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);\n3. Hair pulling daily with urges to pull as the trigger in \\>50% of the episodes of pulling;\n4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;\n5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence\n\nExclusion Criteria:\n\n1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);\n2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;\n3. History of seizures;\n4. Myocardial infarction within 6 months;\n5. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;\n6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;\n7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);\n8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;\n9. Current skin picking disorder;\n10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;\n11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);\n12. Previous treatment with semaglutide;\n13. Use of any weight loss medications;\n14. Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;\n15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;\n16. Recent (30-day) use of illicit drugs except cannabis;\n17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment;\n18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B;\n19. History of pancreatitis.","ALL","18 Years","75 Years",{"count":49,"type":50},10,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.",[56,57,58,59,60],"Trichotillomania (Hair-Pulling Disorder)","Trichotillomania","Hair Pulling Disorder","Hair Pulling","Hair-Pulling Disorder",[62,63],"trichotillomania","hair pulling","NOT_YET_RECRUITING","2026-06-08",{"date":67,"type":68},"2026-06-10","ACTUAL",{"date":70,"type":50},"2026-06",{"date":72,"type":50},"2027-02",{"name":5,"class":6}]